Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Tiebo Mao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7188-9538; OpenAlex author ID A5077929965. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2021: 4 papers · 2022: 8 papers · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper

Papers 18

  1. Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis. Co-author DOI 10.1016/j.xcrm.2025.101928↗
  2. Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib. Co-author DOI 10.1186/s12943-024-01965-5↗
  3. The Role of Bile Acids in Pancreatic Cancer. Co-author DOI 10.2174/0115680096281168231215060301↗
  4. PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. Co-author DOI 10.1016/j.canlet.2023.216095↗
  5. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216206↗
  6. Cuproptosis-related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients. Co-author DOI 10.1049/syb2.12068↗
  7. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. First author DOI 10.1002/cac2.12238↗
  8. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. First author DOI 10.1016/j.ebiom.2022.103897↗
  9. Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer. Co-author DOI 10.1155/2022/5634887↗
  10. HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. Co-author DOI 10.1186/s12935-022-02807-4↗
  11. Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer. First author DOI 10.18632/aging.204031↗
  12. A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. Co-author DOI 10.3389/fcell.2022.1001606↗
  13. Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. Co-author DOI 10.3389/fcell.2022.942225↗
  14. A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer. Co-author DOI 10.3390/ijms24010156↗
  15. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Co-author DOI 10.1038/s41421-021-00271-4↗
  16. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08375-6↗
  17. A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer. Co-author DOI 10.21037/tcr-20-3478↗
  18. CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling pathway. Co-author DOI 10.7150/jca.54482↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiujie Cui · 16 shared papers, 2021–2024 · strength 2.23
  2. Xiaofei Zhang · 15 shared papers, 2021–2024 · strength 2.13
  3. Weiyu Ge · 11 shared papers, 2022–2024 · strength 1.57
  4. Shengbai Xue · 9 shared papers, 2022–2024 · strength 1.35
  5. Liwei Wang · 8 shared papers, 2021–2023 · strength 1.08
  6. Jiayu Yao · 8 shared papers, 2021–2022 · strength 0.97
  7. Liwei Wang · 4 shared papers, 2022–2025 · strength 0.73
  8. Feng Jiao · 5 shared papers, 2021–2022 · strength 0.56
  9. Shumin Li · 4 shared papers, 2022–2023 · strength 0.55
  10. Yanling Wang · 3 shared papers, 2022–2024 · strength 0.50
  11. Jiong Hu · 4 shared papers, 2021–2022 · strength 0.43
  12. Haiyan Yang · 3 shared papers, 2021–2024 · strength 0.42
  13. Yanling Wang · 3 shared papers, 2022–2023 · strength 0.41
  14. Liwei Wang · 3 shared papers, 2021 · strength 0.34
  15. Ming Quan · 2 shared papers, 2023–2024 · strength 0.34
  16. Jing Xue · 2 shared papers, 2021–2025 · strength 0.32
  17. Yu Wang · 3 shared papers, 2021–2022 · strength 0.32
  18. Yongwei Sun · 3 shared papers, 2021–2022 · strength 0.32
  19. Deliang Fu · 3 shared papers, 2021–2022 · strength 0.32
  20. Xiao Zhang · 2 shared papers, 2021–2022 · strength 0.29
  21. Liwei Wang · 2 shared papers, 2022 · strength 0.26
  22. Yiyi Liang · 2 shared papers, 2021 · strength 0.23
  23. Ping Lu · 1 shared paper, 2025 · strength 0.22
  24. Xuqing Shen · 1 shared paper, 2025 · strength 0.22
  25. Ningning Niu · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.